Electrophilic prostaglandins: identification of protein targets and opportunities for drug discovery
Related Experiment Video
Updated: Apr 1, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
1Centro de Investigaciones Biológicas, C.S.I.C., Chemical and Physical Biology Department, Spain.
Unlabelled:
Electrophilic eicosanoids are endogenous mediators that play complex roles in signaling and adaptive responses. Basal generation of these species contributes to cell homeostasis, whereas their increased generation under situations of oxidative stress may contribute to cell adaptation or cytoprotection, and, if generated in amounts surpassing the cell detoxification mechanisms, may elicit cytotoxicity. Electrophilic prostaglandins with cyclopentenone structure (cyPG) have been shown to exert protective effects in numerous models of inflammation and tissue injury, as well as antitumoral effects. Protein covalent modification is a key mechanism of action of these species. We have used tagged electrophilic PG, mainly cyPG, as tools to characterize electrophilic lipid-protein interactomes. cyPG with different structure elicit the modification of subsets of proteins comprising both common and selective targets. Among the targets identified are proteins involved in inflammatory responses, the modification of which contributes to the anti-inflammatory effects of cyPG, signaling proteins, and proteins involved in chemoprevention, chemoresistance or tumorigenesis. Thus, some cyPG targets, including glutathione transferase and aldo-keto reductases, have broad implications both in redox signaling and as drug targets. We have observed that cyPG effects are highly dependent on cell type, context, and levels of both cyPG and endogenous antioxidants, in particular GSH. Moreover, the ability of cyPG to display biphasic or dual actions and the nature of the proteins modified depend on these factors. A detailed knowledge of cyPG targets and of the factors that modulate protein modification will contribute to the understanding of their mechanisms of action and define their potential as leads for drug discovery, but may also shed light on redox signaling mechanisms.
Funding:
MINECO SAF2012-36519, ISCIII RD12/0013/0008 (Spain), EU COST Action CM1001.
More Related Videos
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenomics: Identification of New Drug Targets
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Protein-protein Interfaces